Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated April 12, 2022.

Dr Reddy’s: Improving exposure to EMs adds to investment case

Situation in Russia presents an opportunity for Indian pharma companies to gain market share in Russia

Buy Dr Reddy’s Labs; target of Rs 5160: Motilal Oswal

Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5160 in its research report dated January 29, 2022.

Buy Dr Reddys Laboratories; target of Rs 5160: ICICI Direct

ICICI Direct is bullish on Dr Reddys Laboratories has recommended buy rating on the stock with a target price of Rs 5160 in its research report dated January 29, 2021.

Dr Reddy’s: Supported by traction in limited competition products

Sales growth in North America was helped by healthy market share for the generic version of Vascepa

Buy Dr. Reddy’s Laboratories: target of Rs 5900: Sharekhan

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5900 in its research report dated December 24, 2021.

Buy Dr Reddy’s Labs; target of Rs 5470: Motilal Oswal

Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5470 in its research report dated October 30, 2021.

Dr Reddy’s: Aced by emerging markets' growth

While DRL is hit by pricing erosion in the US business, potential growth in the limited competition products underlines a positive outlook

Buy Dr Reddy’s Laboratories: target of Rs 5900: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5900 in its research report dated September 06, 2021.

Hold Dr Reddy’s Laboratories: target of Rs 5250: ICICI Direct

ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 5250 in its research report dated July 28, 2021.

Dr Reddy’s: Growth story remains intact; margins key monitorable

Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium term

Dr Reddy’s: COVID opportunity gets wings

Along with Sputnik V and 2-DG, Dr Reddys has further strengthened its COVID opportunity, which makes it a worthy watch

Accumulate Dr Reddy's Laboratories; target of Rs 5400: Dolat Capital Market

Dolat Capital Market recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5400 in its research report dated April 12, 2021.

Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated March 04, 2021.

Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market

Dolat Capital Market is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5200 in its research report dated January 31, 2021.

Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 29, 2021.

Cadila: COVID vaccine to be the key differentiator in the near term

In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion

Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5406 in its research report dated January 30, 2021.

Weekly Tactical Pick | Dr Reddy's Laboratories

Vaccine scope, strong product pipeline to act as tonic for Dr Reddy's Laboratories

Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct

ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5525 in its research report dated January 30, 2021.

Neutral Dr Reddy’s Labs; target of Rs 5070: Motilal Oswal

Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 5070 in its research report dated January 30, 2021.

Dr Reddy’s: Should we look beyond impairments?

Large part of impairment charge taken by Dr Reddy's is explained by the erosion in the value of Nuvaring due to the launch of the additional generic product by Teva

Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

We believe dominance of profit/royalty-sharing aspect in the business model distinguishes Gland Pharma from other contract manufacturers

Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated January 12, 2021.

COVID Vaccine: The opportunities for investors - Part I

Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation